Last update 30 Aug 2025

64Cu-DOTA-pembrolizumab

Overview

Basic Info

Drug Type
Radiolabeled antibody, Diagnostic radiopharmaceuticals
Synonyms
64Cu-pembrolizumab, Copper Cu 64 Pembrolizumab
Target
PD-1
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Therapeutic Areas
Neoplasms
Active Indication-
Inactive Indication
Metastatic Solid TumorSolid tumor
Originator Organization-
Active Organization-
Inactive Organization
City of Hope National Medical CenterCity of Hope National Medical Center
License Organization-
Drug Highest PhaseDiscontinuedEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with 64Cu-DOTA-pembrolizumab
NCT05728372
/ WithdrawnEarly Phase 1IIT
Pilot Trial Using 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy for Oligo-Progressive Solid Tumors
100 Clinical Results associated with 64Cu-DOTA-pembrolizumab
Login to view more data
100 Translational Medicine associated with 64Cu-DOTA-pembrolizumab
Login to view more data
100 Patents (Medical) associated with 64Cu-DOTA-pembrolizumab
Login to view more data
100 Deals associated with 64Cu-DOTA-pembrolizumab
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Solid TumorPhase 1-
City of Hope National Medical CenterCity of Hope National Medical Center
25 Aug 2023
Solid tumorPhase 1-
City of Hope National Medical CenterCity of Hope National Medical Center
25 Aug 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free